An apparatus (100; 200; 230; 400; 420; 440; 470; 500; 515; 600a; 600b; 620; 650; 680; 700; 730; 1010; 1020; 1115; 1910) CHARACTERIZED BY: an elongate member (240; 638; 740) comprising a distal tip (550; 565; 1013; 1024; 1030; 1040; 1052; 1060; 1070; 1400), the distal tip configured to fit within a lumen of a body of a subject, the elongate member configured to extend from outside the body, through an entry site on the body, and into the lumen; wherein the distal tip comprises a plurality of elements, the plurality of elements arranged on the distal tip such that biasing the distal tip engages one or more of the plurality of elements with a wall of the lumen; wherein the plurality of elements comprises at least one chemical delivery element (600a,b; 652a,b; 624a-e; 680; 1020; 1036a,b; 1054) and at least one sensory circuit (210; 250; 415; 435; 520; 605a,b; 632a,b; 658a,b; 662; 710; 745; 1021a,b; 1028; 1032a-f; 1044; 1066; 1074; 1410; 1435; 1530; 1570; 1620; 1625), the at least one chemical delivery element comprising one or more probes, at least one of the one or more probes being configured to penetrate through the wall responsive to actuation by a controller; wherein at least one of the one or more probes is configured, responsive to feedback from the at least one sensory circuit, to deliver a composition of matter to a tissue site beyond the wall of the lumen to apply a block to a target region of the subj ect; wherein the composition of matter comprises at least one of a neurolytic agent and an inflammatory agent for use in blocking at least one of one or more nerves and one or more lymphatic ducts in the target region by at least one of alteration of a structure of a perineural sheath of at least one of the one or more nerves, architectural destruction of at least one of nerve tissue and lymphatic duct tissue via inflammation, and formation of scar tissue along at least one of the one or more nerves and the one or more lymphatic ducts; wherein at least one of the one or more probes is configured to apply the block to the target region by injecting the neurolytic agent of the composition of matter into at least one of the one or more nerves, the one or more lymphatic ducts, and tissue nearby at least one of the one or more nerves and the one or more lymphatic ducts, and at least one other of the one or more probes is configured to apply the block to the target region by injecting the inflammatory agent of the composition of matter into at least one of an artery and a vein nearby at least one of the one or more nerves and the one or more lymphatic ducts; and wherein the feedback from the at least one sensory circuit comprises a quantification of nerve activity of the one or more nerves in the target region. an elongate member (240; 638; 740) comprising a distal tip (550; 565; 1013; 1024; 1030; 1040; 1052; 1060; 1070; 1400), the distal tip configured to fit within a lumen of a body of a subject, the elongate member configured to extend from outside the body, through an entry site on the body, and into the lumen; wherein the distal tip comprises a plurality of elements, the plurality of elements arranged on the distal tip such that biasing the distal tip engages one or more of the plurality of elements with a wall of the lumen; wherein the plurality of elements comprises at least one chemical delivery element (600a,b; 652a,b; 624a-e; 680; 1020; 1036a,b; 1054) and at least one sensory circuit (210; 250; 415; 435; 520; 605a,b; 632a,b; 658a,b; 662; 710; 745; 1021a,b; 1028; 1032a-f; 1044; 1066; 1074; 1410; 1435; 1530; 1570; 1620; 1625), the at least one chemical delivery element comprising one or more probes, at least one of the one or more probes being configured to penetrate through the wall responsive to actuation by a controller; wherein at least one of the one or more probes is configured, responsive to feedback from the at least one sensory circuit, to deliver a composition of matter to a tissue site beyond the wall of the lumen to apply a block to a target region of the subj ect; wherein the composition of matter comprises at least one of a neurolytic agent and an inflammatory agent for use in blocking at least one of one or more nerves and one or more lymphatic ducts in the target region by at least one of alteration of a structure of a perineural sheath of at least one of the one or more nerves, architectural destruction of at least one of nerve tissue and lymphatic duct tissue via inflammation, and formation of scar tissue along at least one of the one or more nerves and the one or more lymphatic ducts; wherein at least one of the one or more probes is configured to apply the block to the target region by injecting the neurolytic agent of the composition of matter into at least one of the one or more nerves, the one or more lymphatic ducts, and tissue nearby at least one of the one or more nerves and the one or more lymphatic ducts, and at least one other of the one or more probes is configured to apply the block to the target region by injecting the inflammatory agent of the composition of matter into at least one of an artery and a vein nearby at least one of the one or more nerves and the one or more lymphatic ducts; and wherein the feedback from the at least one sensory circuit comprises a quantification of nerve activity of the one or more nerves in the target region.